SCHEMBL617072

SCHEMBL617072

Nc1ncc(N2CCN(C(=O)N3CCOCC3)CC2)nc1C(=O)Nc1ccccn1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
HPGD P15428 1/20 0.56
HSD17B10 Q99714 1/20 0.56
GRM5 P41594 8/20 0.56
ATR Q13535 6/20 0.50
PRKCA P17252 2/20 0.45
PRKCQ Q04759 2/20 0.45
BTK Q06187 1/20 0.45
AKR1C3 P42330 2/20 0.44
HTR2B P41595 1/20 0.43
GSK3B P49841 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL617820 0.91 GRM5 (0.59) KDM4EALDH1A1HPGDHSD17B10GRM5
SCHEMBL616530 0.90 GRM5 (0.58) KDM4EALDH1A1HPGDHSD17B10GRM5
SCHEMBL618481 0.88 GRM5 (0.53) GRM5ATRPRKCAPRKCQBTK
SCHEMBL615928 0.86 GRM5 (0.64) ALDH1A1HPGDHSD17B10GRM5ATR
SCHEMBL615929 0.84 GRM5 (0.58) ALDH1A1GRM5ATR
SCHEMBL617715 0.84 GRM5 (0.61) KDM4EALDH1A1HPGDHSD17B10GRM5
SCHEMBL614451 0.84 GRM5 (0.58) GRM5ATR
SCHEMBL10255558 0.83 GRM5 (0.60) ALDH1A1GRM5ATRBTK
SCHEMBL616624 0.83 GRM5 (0.60) KDM4EALDH1A1HSD17B10GRM5ATR
SCHEMBL618071 0.83 GRM5 (0.60) KDM4EALDH1A1HSD17B10GRM5ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140113005-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-04-24 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
EP-2370424-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2011-10-05 EP disclosed
WO-2010054398-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113005-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 KDM4E 2868/4885ALDH1A1 3958/4885HPGD 3285/4885
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 KDM4E 2868/4885ALDH1A1 3958/4885HPGD 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.